Abbott and the NIH will put their heads together
Abbott Laboratories announced on 5/14/2019 that it has partnered with the National Institutes of Health to support the agency’s BRAIN initiative, which aims to accelerate neuroscience research and advancements. Although Abbott is a major biotech company in the US, it actually lacks patents for technology using artificial intelligence in the neurology field. On the other hand, the NIH has an extensive patent portfolio in the AI Biotech/Diagnostics sector, many of which relate to specific neurological or psychiatric conditions such as Parkinson’s disease and epilepsy. Will Abbott realize the value of artificial intelligence in the biotech field through this private-public partnership?
Related Posts
Cala Health Claims to Have the only Patented Neurostimulation for Essential Tremor Treatment. The Patent Data Disagrees
Cala Health has figured out that innovations backed by patents make them exponentially more valuable in the marketplace. However, in a zest…
Capital One is Investing in AI Biotech? What’s in their wallet?
In the past 18 months, Capital One has expanded past its usual banking activities, and begun exploring the AI Biotech Sector. But do they…
Google AI Reinvents Speech Recognition. Who will follow?
There is no doubt that the big 5 tech companies (Apple, Amazon, Google, Facebook, and Microsoft) have developed massive IP portfolios in…